Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Oct 2, 2020

(R) Cantargia reports first patient treated with CAN04 in a US phase I study investigating combination with pembrolizumab

Sep 23, 2020

(R) Cantargia reports high response rates with CAN04 combination therapy in NSCLC and presents next development steps

Sep 21, 2020

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

Sep 21, 2020

(R) Cantargia’s nomination committee proposes a new board member

Aug 20, 2020

(R) Cantargia publishes half year report

Jul 31, 2020

(R) New number of shares and votes in Cantargia

Jun 23, 2020

(R) Cantargia strengthens management team with VP Regulatory Affairs and VP CMC

Jun 22, 2020

(R) Cantargia presents new preclinical data on CAN04 at the 2020 AACR Annual Meeting

May 27, 2020

(R) Annual General Meeting in Cantargia AB (publ)

May 27, 2020

(R) Cantargia publishes interim report for first quarter 2020

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye